Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department

Cortlyn Brown, MD; Jeanne Noble, MD; Zlatan Coralic, PharmD

Disclosures

Western J Emerg Med. 2020;21(3):510-513. 

In This Article

Abstract and Introduction

Abstract

As of March 30th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine.[2] We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective.

Introduction

As of March 30th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States,[1] with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine.[2] We present a brief overview of the potential prophylactic and treatment agents under investigation, some of which could be initiated in the ED if proven effective.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....